Evidence for Keltican in Diabetic Neuropathy
Keltican is not recommended for diabetic peripheral neuropathy based on current evidence-based guidelines, which consistently recommend gabapentinoids, SNRIs, tricyclic antidepressants, or sodium channel blockers as first-line pharmacologic treatments for neuropathic pain. 1, 2
Why Keltican Is Not Guideline-Recommended
The most recent and authoritative diabetes care guidelines (2023-2024) from the American Diabetes Association make no mention of vitamin B combinations like Keltican for treating diabetic neuropathy 1, 2. Instead, these guidelines explicitly state that "no compelling evidence exists in support of glycemic control or lifestyle management as therapies for neuropathic pain in diabetes or prediabetes, which leaves only pharmaceutical interventions" referring specifically to gabapentinoids, SNRIs, TCAs, and sodium channel blockers 1.
The Limited Evidence for Keltican
Only one small, open-label study (n=40) from 2002 examined Keltican specifically 3. This study showed trends toward improvement in neuropathy scores and sural nerve conduction velocity over 3 months, but this represents:
- Low-quality evidence: Open-label design without placebo control
- Small sample size: Only 40 patients
- Outdated: Published over 20 years ago
- Not replicated: No subsequent confirmatory trials
What the Evidence Actually Shows About Individual B Vitamins
While Keltican contains thiamine, pyridoxine, and cyanocobalamin, the evidence for these components individually is mixed:
Thiamine (Vitamin B1):
- May have theoretical benefits for diabetic complications based on in vitro and animal studies 4
- No large-scale randomized controlled trials in humans have been conducted 4
- FDA-approved only for thiamine deficiency states, not diabetic neuropathy 5
Pyridoxine (Vitamin B6):
- One cross-sectional study found 51.8% prevalence of pyridoxine deficiency in diabetic neuropathy patients with inverse correlation to nerve conduction velocity 6
- This shows association, not causation, and does not prove supplementation efficacy
Vitamin B12 (Cyanocobalamin):
- Deficiency associated with neuropathy development 7
- A 2026 meta-analysis of vitamin B supplementation showed modest improvements in Michigan Neuropathy Screening Instrument scores but did not reach the minimal clinically important difference 8
- Combination B-vitamin regimens appeared numerically better than monotherapy, but formal subgroup analysis showed inconsistent results 8
Magnesium and Calcium:
- Low magnesium linked to neuropathy presence, but optimal therapeutic intervention not identified 9, 7
- No specific evidence for calcium supplementation in diabetic neuropathy
What You Should Use Instead
First-line pharmacologic treatments (in order of guideline strength) 1, 2:
- Gabapentinoids (pregabalin 300-600 mg/day or gabapentin 900-3600 mg/day)
- SNRIs (duloxetine 60-120 mg/day - FDA approved for diabetic neuropathic pain)
- Tricyclic antidepressants (amitriptyline 25-75 mg/day, start low at 10 mg in elderly)
- Sodium channel blockers
Critical caveats:
- Start TCAs at 10 mg/day in older patients due to anticholinergic effects and cardiac risks 10
- Avoid doses >100 mg/day of TCAs due to increased sudden cardiac death risk 10
- Gabapentinoids may cause edema and require dose adjustment in elderly 1
- Duloxetine contraindicated in hepatic disease 10
The Only Disease-Modifying Approach with Evidence
Optimize glycemic control - this is the only intervention proven to prevent or delay neuropathy development in type 1 diabetes and slow progression in type 2 diabetes 1, 2. Additionally:
- Blood pressure control reduces neuropathy risk (OR 1.58 for hypertension) 1
- Lipid control is important, though statins/fenofibrates don't prevent DPN 1
Bottom Line
Keltican lacks the rigorous evidence base required for guideline recommendation. If you're considering it because a patient has documented B-vitamin deficiencies, address those deficiencies directly with appropriate supplementation while using proven first-line agents for neuropathic pain management. Do not use Keltican as monotherapy or substitute it for evidence-based treatments. Refer to a neurologist or pain specialist if adequate pain control is not achieved with first-line agents 1, 2.